Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acquired Resistance to KRASG12C Inhibition in Cancer
Mark M. Awad, Shengwu Liu, Igor I. Rybkin, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 25, pp. 2382-2393
Open Access | Times Cited: 438

Showing 26-50 of 438 citing articles:

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer
Joshua K. Sabari, Vamsidhar Velcheti, K. Shimizu, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 15, pp. 3318-3328
Open Access | Times Cited: 89
KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy
Meagan B. Ryan, Oluwadara Coker, Alexey V. Sorokin, et al.
Cell Reports (2022) Vol. 39, Iss. 12, pp. 110993-110993
Open Access | Times Cited: 86
Therapeutic KRAS G12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers
Edurne Mugarza, Febe van Maldegem, Jesse Boumelha, et al.
Science Advances (2022) Vol. 8, Iss. 29
Open Access | Times Cited: 86
Therapeutic landscape and future direction of metastatic colorectal cancer
Hideaki Bando, Atsushi Ohtsu, Takayuki Yoshino
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 5, pp. 306-322
Closed Access | Times Cited: 84
Drugging KRAS: current perspectives and state-of-art review
Kaushal Parikh, Giuseppe Luigi Banna, Stephen V. Liu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 83
Adagrasib: First Approval
Sohita Dhillon
Drugs (2023) Vol. 83, Iss. 3, pp. 275-285
Closed Access | Times Cited: 82
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
Grace K. Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 18, pp. 3311-3317
Open Access | Times Cited: 79
Arginase 1 is a key driver of immune suppression in pancreatic cancer
Rosa E. Menjivar, Zeribe C. Nwosu, Wenting Du, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 76
Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
Yi‐Hsuan Tsai, Mark G. Woodcock, Salma H. Azam, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 4
Open Access | Times Cited: 75
KRAS is vulnerable to reversible switch-II pocket engagement in cells
James D. Vasta, D. Matthew Peacock, Qinheng Zheng, et al.
Nature Chemical Biology (2022) Vol. 18, Iss. 6, pp. 596-604
Open Access | Times Cited: 75
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Shubham Pant, Zev A. Wainberg, Colin D. Weekes, et al.
Nature Medicine (2024) Vol. 30, Iss. 2, pp. 531-542
Open Access | Times Cited: 74
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 994-1017
Open Access | Times Cited: 74
Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders
Alexander Hanzl, Ryan Casement, Hana Imrichová, et al.
Nature Chemical Biology (2022) Vol. 19, Iss. 3, pp. 323-333
Open Access | Times Cited: 73
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
Jessica Lee, Smruthy Sivakumar, Alexa B. Schrock, et al.
npj Precision Oncology (2022) Vol. 6, Iss. 1
Open Access | Times Cited: 73
Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 927-936
Open Access | Times Cited: 55
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Jayesh Desai, Guzmán Alonso, Se Hyun Kim, et al.
Nature Medicine (2023) Vol. 30, Iss. 1, pp. 271-278
Open Access | Times Cited: 53
Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS
Yuta Adachi, Ryo Kimura, Kentaro Hirade, et al.
Nature Cancer (2023) Vol. 4, Iss. 6, pp. 829-843
Closed Access | Times Cited: 47
Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
E O'Sullivan, Anna Keogh, Brian E. Henderson, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1635-1635
Open Access | Times Cited: 45
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
Xiangdong Lv, Xuan Lu, Jin Cao, et al.
Science (2023) Vol. 381, Iss. 6662
Open Access | Times Cited: 45
Oncogenic KRAS Drives Lipofibrogenesis to Promote Angiogenesis and Colon Cancer Progression
Wen‐Hao Hsu, Kyle A. LaBella, Yiyun Lin, et al.
Cancer Discovery (2023) Vol. 13, Iss. 12, pp. 2652-2673
Open Access | Times Cited: 43
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Alex Friedlaender, M. Pérol, Giuseppe Luigi Banna, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 36
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
Amy Rappaport, Chrisann Kyi, Monica Lane, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1013-1022
Closed Access | Times Cited: 30
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Jeffrey A. Klomp, Jennifer E. Klomp, Clint A. Stalnecker, et al.
Science (2024) Vol. 384, Iss. 6700
Open Access | Times Cited: 30

Scroll to top